# A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

> **NCT07632235** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai 6th People's Hospital** · enrollment: 112 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma (Icc)

## Interventions

- **DRUG:** Celecoxib + Pembrolizumab + Gemcitabine/Cisplatin
- **DRUG:** Pembrolizumab + Gemcitabine/Cisplatin

## Key facts

- **NCT ID:** NCT07632235
- **Lead sponsor:** Shanghai 6th People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-15
- **Primary completion:** 2029-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2026-08-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07632235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07632235, "A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07632235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*